Multicenter Phase 2 Trial of ARQ 197 for Subjects With Relapsed or Refractory Germ Cell Tumors.
Phase of Trial: Phase II
Latest Information Update: 28 Feb 2018
At a glance
- Drugs Tivantinib (Primary)
- Indications Germ cell and embryonal neoplasms
- Focus Therapeutic Use
- Sponsors Daiichi Sankyo Inc
- 05 Apr 2012 Additional trial location added as reported by European Clinical Trials Database.
- 02 Mar 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 03 Jun 2010 Additional trial investigator (Quinn D) identified as reported by University of Southern California Norris Comprehensive Cancer Center record.